Drugsrus

What Drugsrus does

Drugsrus Limited is a UK-based pharmaceutical wholesaler and distributor headquartered at 5 Sandridge Close, Harrow, operating under MHRA and Home Office regulatory oversight. Founded in 1984 and active for over 40 years, the company procures branded medicines, generic medicines, surgicals and dressings, diagnostics, medical devices, and nutritional products from a global network of licensed suppliers, and resells them to NHS Trusts and all major UK wholesalers under temperature-controlled logistics. Its 3,000+ ambient, 100+ cold-chain, and 30+ controlled-drug pallet warehouse footprint is approved for Wholesale Distribution Authorisation (WDA), GDP, and GMP operations, and the company holds a separate Home Office licence covering Schedule 2, 3 and 4 controlled drugs.

The business operates three interlocking revenue streams. The first is straightforward wholesale distribution, conducted transactionally on margin between licensors and UK customers. The second is parallel importing, where the company sources products abroad, repackages them under its Manufacturer's Authorisation (MIA), and releases them for UK sale under Parallel Imported Product Licences (PLPIs). The third is generic medicines licensing, delivered through its sister company DAWA Limited, which works with development partners to obtain UK Marketing Authorisations that Drugsrus then distributes via its own channel infrastructure. The company also markets specific products directly, including Glycopyrronium Bromide Tablets.

Drugsrus runs a lean B2B model with 11–50 employees, no disclosed outside funding, no parent company, and ownership structure that is not publicly disclosed. Its go-to-market is exclusively direct and channel-based: the corporate website is used to communicate regulatory credentials and provide contact information to NHS procurement teams and wholesale counterparties. Pricing is not publicly disclosed, and there is no evidence of investment in API, SDK, or software product surface beyond the compliance and operational tooling required for GDP/GMP-grade distribution. The company's moat rests on the combination of regulated licences, cold-chain infrastructure, and long-tenured relationships with NHS Trusts and the major UK wholesaler tier.

Name

Drugsrus

Legal name

Drugsrus Limited

Website

https://drugsrus.co.uk

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

Drugsrus Limited is a UK-based pharmaceutical wholesaler and distributor founded in 1984 that procures branded and generic medicines, surgicals, diagnostics, medical devices, and nutritional products from a global supplier network and distributes them temperature-controlled to NHS Trusts and major UK wholesalers under MHRA, GDP, GMP, and Home Office licences.

Ownership category

akta.pro rank

Product category

Pharmaceutical Wholesale Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

akta.pro secondary industries

Specialty Pharmacy & Biologics Distribution (CRAOAHAD), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical wholesale distribution
• Generic medicines supply
• Parallel import trading
• Cold chain logistics
• Medical device distribution

Headquarters

HQ city

Harrow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Infrastructure, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Wholesale Distribution: Distribution of branded medicines, generic medicines, surgicals and dressings, diagnostics, medical devices, and nutritional products to major wholesalers and NHS Trusts.
2. Parallel Import Trading: Parallel importing of healthcare products including medicines, surgical products, dressings, diagnostics, medical devices and nutritional products. Products are repackaged and released for sale in the UK under Parallel Imported Product Licences (PLPIs).
3. Generic Medicines Licensing: In-licensing and out-licensing of generic medicines. Sister company DAWA Limited works with development partners to apply for UK Marketing Authorisations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

Drugsrus is a UK-based pharmaceutical wholesaler and distributor that procures branded and generic medicines, surgicals and dressings, diagnostics, medical devices, and nutritional products from a global network of fully licensed suppliers. The company stores products in MHRA and Home Office approved temperature-controlled warehouses and distributes them to NHS Trusts and all major UK wholesalers with temperature-controlled delivery. It also conducts parallel import trading, repackaging products under its Manufacturer's Authorisation (MIA) for UK release, and supports generic medicines licensing through its sister company DAWA Limited.

Product overview

Drugsrus is a pharmaceutical wholesaler and distributor offering a portfolio of branded medicines, generic medicines (procured and distributed via sister company DAWA Limited), and parallel imported products (repackaged under their MIA licence). Their product range also includes surgicals and dressings, diagnostics, medical devices, and nutritional products. The company operates temperature-controlled warehouses and distributes to NHS Trusts and major wholesalers across the UK.

Differentiator

Problem solved

Functional benefit

Brands

• Glycopyrronium: Glycopyrronium Bromide Tablets - a specific pharmaceutical product marketed by the company.

Products and services

• Branded Medicines Pharmaceutical products sold under original manufacturer brand names, distributed to NHS Trusts and major UK wholesalers from MHRA-approved temperature-controlled warehouses.
• Generic Medicines Generic pharmaceutical products equivalent to branded drugs, distributed to UK customers with UK Marketing Authorisations obtained via sister company DAWA Limited and manufacturing partnerships with CMOs and R&D specialists.
• Surgicals and Dressings Surgical products and medical dressings for healthcare providers, distributed as part of Drugsrus's healthcare product range to NHS Trusts and major UK wholesalers.
• Diagnostics Diagnostic products for medical testing and analysis, distributed to NHS Trusts and major UK wholesalers as part of Drugsrus's healthcare product range.
• Medical Devices Medical devices for healthcare applications, distributed to NHS Trusts and major UK wholesalers as part of Drugsrus's healthcare product range.
• Nutritional Products Nutritional supplements and healthcare products distributed to NHS Trusts and major UK wholesalers.
• Parallel Imports Healthcare products including medicines, surgical products, dressings, diagnostics, medical devices and nutritional products imported from other markets and repackaged under Parallel Imported Product Licences (PLPIs) for UK release under Drugsrus's Manufacturer's Authorisation (MIA).
• Glycopyrronium Bromide Tablets A specific generic pharmaceutical product (Glycopyrronium Bromide Tablets) marketed under the DAWA brand and distributed through Drugsrus with a dedicated product page.

Named customers2 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• DAWA LimitedcoreStrategic or Co-development PartnerDAWA Limited is Drugsrus's sister company that works with development partners to apply for UK Marketing Authorisations across a range of product types. The relationship enables Drugsrus to offer generic medicines with complete regulatory approval pathways.
• Contract Manufacturers (CMOs)coreStrategic or Co-development PartnerDrugsrus has long-standing partnerships with Contract Manufacturers (CMOs) for pharmaceutical manufacturing and repacking activities under their MIA authorisation. These partnerships support their generic medicines and parallel import operations.
• R&D Specialist CompaniesminorStrategic or Co-development PartnerPartnerships with R&D specialist companies support Drugsrus's generic medicines development and licensing activities.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Aspire Pharma: UK specialty and generics pharmaceutical company that licences, supplies, and distributes branded generics and specialty products via its own MIA and WDA; comparable to Drugsrus's DAWA-driven generics and licensing model.
• Doncaster Pharmaceuticals Group (B&S Group): Independent UK pharmaceutical wholesaler and generics manufacturer with MIA and WDA licences; comparable to Drugsrus as a mid-sized player combining distribution, in-licensed generics (PLPIs and MAs), and CMO partnerships.
• Lexon (UK) Ltd: UK-based parallel import and pharmaceutical distribution company focused on PLPI-led supply to wholesalers and pharmacies; directly comparable to Drugsrus on parallel imports and licensed wholesale distribution.
• Mawdsley-Brooks & Co: UK mid-market pharmaceutical wholesaler supplying branded, generic, and unlicensed/specials medicines with WDA, GMP, MIA, and controlled drugs licences - the closest independent UK mid-cap analogue to Drugsrus by product mix, customer base, and regulatory profile.
• AAH Pharmaceuticals (Phoenix Group UK): UK arm of Phoenix Group and one of the three major full-line wholesalers serving pharmacies, hospitals, and NHS Trusts; competes head-to-head with Drugsrus on breadth of SKUs, cold-chain range, and parallel imports.

Broad incumbents

• Alliance Healthcare (Walgreens Boots Alliance): Largest UK pharmaceutical wholesaler and parent distribution arm of Walgreens Boots Alliance; directly comparable because both distribute branded, generic, and parallel-imported medicines to UK pharmacies and NHS customers with full GDP/WDA compliance.
• Phoenix Group UK: Pan-European pharma distribution and retail platform that owns AAH and Numark in the UK; relevant incumbent peer given its scale advantage in pharma wholesale, parallel imports, and generics to NHS customers.

Emerging players

• BCM Specials / BCM Pharma: UK-based specials and unlicensed medicines manufacturer and wholesaler with MHRA MIA; comparable to Drugsrus's repacking, controlled drugs handling, and supply of niche/special-order pharmaceutical products.
• Specials Pharmaceutical UK (SPUK): UK specials medicines manufacturer and wholesaler with GMP, MIA, and WDA holding a controlled drugs licence; comparable peer for temperature-controlled repacking and licensed UK distribution of niche pharmaceutical ranges.

Regional players

• MediPac Ltd: UK-based pharmaceutical wholesaler and parallel importer holding WDA and MIA licences; comparable peer to Drugsrus on PLPI-led parallel imports and B2B distribution to UK pharmacies and wholesalers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/drugsrus-limited

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drugsrus